Results 121 to 130 of about 6,137,711 (269)

Administering Blinatumomab via Continuous Intravenous Infusion in Pediatric Patients—A Single‐Institution Retrospective Review

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Blinatumomab, a CD19xCD3 bispecific T‐cell engager, has become standard therapy for children with de novo B‐cell acute lymphoblastic leukemia (B‐ALL). This retrospective review describes the experience of blinatumomab administration in pediatric patients.
Julia M. Hurley, Ryleigh Krueger, Kellie Joyce, James Stanley, Mary Waskerwitz‐Freyer, Marielle Klunder, David J. Hoogstra   +6 more
wiley   +1 more source

Occurrence of Extramedullary Relapses in Pediatric Acute Lymphoblastic Leukemia After Treatment With Blinatumomab

Pediatric Blood &Cancer, EarlyView.
ABSTRACT We report a retrospective single‐center analysis of pediatric patients with relapsed or refractory B‐cell precursor acute lymphoblastic leukemia focusing on relapses outside of the typical locations, bone marrow, central nervous system, or testes.
Johanna Kunz, Martin Ebinger, Michaela Döring, Markus Mezger, Ursula Holzer, Rupert Handgretinger, Peter Lang, Manon Queudeville   +7 more
wiley   +1 more source

Evaluating the Readability of Patient‐Facing Online Educational Materials for Pediatric Leukemia and Lymphoma

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Together, leukemia and lymphoma account for 38.7% of newly diagnosed pediatric cancer cases in the United States each year. Many caregivers utilize online resources to inform medical health decisions. Understanding the readability of these materials is critical to ensuring comprehensible patient education.
Chloe Strege, Simone Intriago Tito, Courtney Popp, William C. Miller, Cindy Eide, Christen Ebens, Jakub Tolar   +6 more
wiley   +1 more source

Improvement of Sickle Cell Disease Care Mitigates the Healthcare Utilization Induced by Increased Prevalence: Experience of a Tertiary Pediatric Center

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Sickle cell disease (SCD) has undergone major changes in the last decades. Its prevalence has been steadily increasing and numerous advances have been made in the management of the disease. However, the effect in real‐life setting of these major changes is unknown, particularly in a Canadian environment. Procedure We aimed to assess
Maude Cigna, Alexia Muresan, Estelle Lecluze, Karine Leduc, Nathalie Fournier, Maria Tamer, Jean‐François Delisle, Jeremi Charbonneau, Annie Viau, Jessica Darilus, Marie‐Joëlle Doré‐Bergeron, Valérie Arsenault, Evelyne Doyon‐Trottier, Stéphanie Forte, Nancy Robitaille, Yves Pastore, Thomas Pincez   +16 more
wiley   +1 more source

Pleiotropic shared heritability quantifies the shared genetic variance of common diseases. [PDF]

Nat Genet
Zhao Y, Strober B, Hou K, Kerner G, Danesh J, Gazal S, Cheng W, Inouye M, Price AL, Jiang X.   +9 more
europepmc   +1 more source

Graves’ Disease [PDF]

New England Journal of Medicine, 2016
Smith, Terry J, Hegedüs, Laszlo
openaire   +7 more sources

Secretory Phospholipase A2 in Patients With Sickle Cell Disease Hospitalized for Vaso‐Occlusive Pain Episodes

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Secretory phospholipase A2 (sPLA2) is an inflammatory mediator linked to acute chest syndrome (ACS) in sickle cell disease (SCD), a serious complication that can develop during an acute vaso‐occlusive pain episode (VOE). Plasma sPLA2 levels have been proposed as a potential biomarker for predicting ACS onset.
Rawan Korman, Maria Yasmine, Dunia Hatabah, Noor Alzraikat, Frank Harris, Lou Ann Brown, Satheesh Chonat, Nitya Bakshi, Chris A. Rees, Carlton Dampier, Claudia R. Morris   +10 more
wiley   +1 more source

Trends of autoimmune diseases in men and inequities in healthcare access and quality in young, working and postworking individuals: a global analysis of 32-year epidemiological study. [PDF]

BMJ Public Health
Cao F, Wang Y, Chen X, Yang H, Yang W, Tain M, Tao L, Jiang Z, Hou S.   +8 more
europepmc   +1 more source

A Bibliometric Analysis of Publications in Uremic Toxins From 1991 to 2024

Therapeutic Apheresis and Dialysis, EarlyView.
ABSTRACT Background Uremic toxins are a growing area of research in nephrology, with significant implications in the progression and treatment of chronic kidney disease (CKD) and the management of end‐stage kidney disease (ESKD). This bibliometric analysis aims to evaluate the global research trends, key contributors, and the impact of publications in ...
Yuh‐Shan Ho, Karim M. Soliman, Wisit Cheungpasitporn, Wannasit Wathanavasin, Ahmed Daoud, Ahmed I. Kamal, Balázs Szamosfalvi, Tibor Fülöp   +7 more
wiley   +1 more source

Impact of heat on respiratory health: Age- and sex-specific risks in a nationwide Korean study (2014-2019). [PDF]

Int J Biometeorol
Ahn J, Oh J, Kwon HJ, Lim H, Choi J, Bae S, Kim KN, Kim MJ, Kim JH, Lim YH.   +9 more
europepmc   +1 more source